AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9177952 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide (both doses)
Number of subjects: 578
Study 9177952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 578
Study 8479230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg three times per day for the first month, then 100 mg three times per day for the next two months
Number of subjects: 137
Study 8479230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 2870610 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin gel adhesive administered transdermally by an adhesive (Topinitro), 2.5‐10 mg/day, individually titrated for 28 days
Number of subjects: 20
Study 2870610 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 2843039 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-potency inactivated polio vaccines
Number of subjects: 1114
Study 2843039 — intervention group
Group type: COMPARATOR
Intervention: Oral polio vaccine
Number of subjects: 1114
Study 2843039 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine
Number of subjects: 1114
Study 31321573 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 40
Study 31321573 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA+PRF
Number of subjects: 40
Study 31321573 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 40
Study 31321573 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 31373272 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (Space from Depression), delivered over 8 weeks, 7 modules.
Number of subjects: 216
Study 28661316 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/d soya protein
Number of subjects: 20
Study 28661316 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g/d soya protein
Number of subjects: 20
Study 28661316 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g/d soya protein)
Number of subjects: 20
Study 25261801 — intervention group
Group type: COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 103
Study 25261801 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vapo-enucleation of the prostate
Number of subjects: 103
Study 23839277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (10 µg) with 2.6 ml of 0.5% hyperbaric bupivacaine (13 mg)
Number of subjects: 72
Study 23839277 — intervention group
Group type: COMPARATOR
Intervention: Control group with 2.8 ml of 0.5% hyperbaric bupivacaine (14 mg)
Number of subjects: 72
Study 21703206 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg/day from week 20 to 32 of gestation (n=135)
Number of subjects: 229
Study 21703206 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (n=94)
Number of subjects: 229
Study 21703206 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine treatment
Number of subjects: 229
Study 19307526 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride, 850 mg, added to insulin therapy (1-3 times daily)
Number of subjects: 390
Study 16862062 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection as an acute ARF insult
Number of subjects: 112
Study 16862062 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors vs. non-survivors
Number of subjects: 112
Study 16862062 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 112
Study 16862062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate in patients with ARF
Number of subjects: 112
Study 16862062 — intervention group
Group type: EXPERIMENTAL
Intervention: ARF due to sepsis
Number of subjects: 112
Study 16862062 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation disorder, liver and cardiovascular dysfunction
Number of subjects: 112
Study 11818309 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio‐computer assisted self‐interviewing (audio‐CASI)
Number of subjects: 1417
Study 11818309 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face interviews
Number of subjects: 1417
Study 10412755 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E coated cellulose membrane dialyzer
Number of subjects: 0
Study 10412755 — intervention group
Group type: COMPARATOR
Intervention: Ordinary cellulose membrane dialyzer
Number of subjects: 0
Study 7593508 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective salpingography
Number of subjects: 66
Study 7593508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal catheterization
Number of subjects: 66
Study 7593508 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guide cannulation
Number of subjects: 66
Study 2246698 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf (5 ml/kg dose)
Number of subjects: 385
Study 2246698 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 385
Study 2246698 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 385
Study 6772366 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3
Number of subjects: 15
Study 6772366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30098819 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic therapeutic tape
Number of subjects: 26
Study 30098819 — intervention group
Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 26
Study 27552585 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intranasal oxytocin (32 IU per day)
Number of subjects: 60
Study 27552585 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intranasal oxytocin (16 IU per day)
Number of subjects: 60
Study 27552585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25712685 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab (15 mg/kg) plus epirubicin, cisplatin, and capecitabine (ECX)
Number of subjects: 0
Study 25712685 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab (7.5 mg/kg) plus ECX
Number of subjects: 0
Study 25712685 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ECX
Number of subjects: 0
Study 23052526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen 1.5-cm wrap
Number of subjects: 153
Study 23052526 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet 3-cm wrap
Number of subjects: 153
Study 23052526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen 3-cm wrap
Number of subjects: 153
Study 23052526 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet 1.5-cm wrap
Number of subjects: 153
Study 23052526 — intervention group
Group type: COMPARATOR
Intervention: 1.5-cm Toupet
Number of subjects: 153
Study 23052526 — intervention group
Group type: COMPARATOR
Intervention: 3-cm Nissen
Number of subjects: 153
Study 23052526 — intervention group
Group type: COMPARATOR
Intervention: 1.5-cm wrap
Number of subjects: 153
Study 23052526 — intervention group
Group type: COMPARATOR
Intervention: 3-cm wrap
Number of subjects: 153
Study 21967952 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system containing an antibacterial monomer
Number of subjects: 15
Study 21967952 — intervention group
Group type: COMPARATOR
Intervention: Conventional adhesive system (control)
Number of subjects: 15
Study 18774439 — intervention group
Group type: EXPERIMENTAL
Intervention: Various therapeutic management options for early PD
Number of subjects: 0
Study 18774439 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17140447 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (prolonged stretching and resistance training)
Number of subjects: 180
Study 17140447 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 180
Study 17140447 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 180
Study 12695957 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty using the transgluteal approach
Number of subjects: 209
Study 11078982 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement (2 IU GH/m daily for 4 months)
Number of subjects: 24
Study 11078982 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement
Number of subjects: 24
Study 11078982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8862480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (vitamin E, 15 mg and vitamin C, 120 mg) and beta-carotene, 6 mg
Number of subjects: 575
Study 8862480 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace elements (zinc, 20 mg, selenium, 100 micrograms)
Number of subjects: 575
Study 8862480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins associated with trace elements
Number of subjects: 575
Study 8862480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study 1799477 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b in a dose of 5 million units (MU) three times per week
Number of subjects: 120
Study 1799477 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 120
Study 1799477 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 120
Study 6877590 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal mobility
Number of subjects: 120
Study 6877590 — intervention group
Group type: COMPARATOR
Intervention: Bed rest for 24 hours
Number of subjects: 120
Study 30847639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint snacks (SS) - 3×20-s 'all out' cycling bouts separated by 1-4-h rest (n=12)
Number of subjects: 28
Study 30847639 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Sprint Interval Training (SIT) - 3×20-s bouts interspersed with 3-min rest within a 10-min training session (n=16)
Number of subjects: 28
Study 30592751 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM screening by capillary glucose testing, counselling on nutrition and exercise, follow-up through health center
Number of subjects: 210
Study 30592751 — intervention group
Group type: COMPARATOR
Intervention: Routine practice at control facilities
Number of subjects: 210
Study 30592751 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM screening and management intervention
Number of subjects: 210
Study 27647873 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 300 mg
Number of subjects: 0
Study 27647873 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 1000 mg
Number of subjects: 0
Study 27647873 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg (intranasal)
Number of subjects: 0
Study 27647873 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 200 mg (intranasal)
Number of subjects: 0
Study 27647873 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 30 mg
Number of subjects: 0
Study 27647873 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 60 mg
Number of subjects: 0
Study 27647873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral study)
Number of subjects: 0
Study 27647873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasal study)
Number of subjects: 0
Study 23808615 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg amitriptyline
Number of subjects: 10
Study 23808615 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg paroxetine
Number of subjects: 10
Study 23808615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23000875 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-phospholipids, melatonin and tryptophan supplementation
Number of subjects: 25
Study 23000875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19913360 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 34
Study 19913360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol Awakening Response (CAR)
Number of subjects: 34
Study 19913360 — intervention group
Group type: COMPARATOR
Intervention: Heart rate response to TSST
Number of subjects: 34
Study 18788648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg
Number of subjects: 43
Study 18788648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15721000 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic lecture on acute appendicitis (Group A)
Number of subjects: 126
Study 15721000 — intervention group
Group type: COMPARATOR
Intervention: Standardized patient interaction (SPI) on acute appendicitis (Group B)
Number of subjects: 126
Study 12682318 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa therapy
Number of subjects: 40
Study 12682318 — intervention group
Group type: COMPARATOR
Intervention: L-dopa-naive (control group)
Number of subjects: 40
Study 10373047 — intervention group
Group type: EXPERIMENTAL
Intervention: IFR flight mission (40-min duration)
Number of subjects: 35
Study 10373047 — intervention group
Group type: COMPARATOR
Intervention: Control session on land
Number of subjects: 35
Study 9441116 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 7S collagen concentration in patients with IPF
Number of subjects: 0
Study 9441116 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment in IPF patients
Number of subjects: 0
Study 9441116 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of serum 7S collagen
Number of subjects: 0
Study 1417133 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN gamma)
Number of subjects: 0
Study 1417133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6391270 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1-2 mg)
Number of subjects: 0
Study 6391270 — intervention group
Group type: COMPARATOR
Intervention: Innovar (fentanyl and droperidol, 2.5-5 ml)
Number of subjects: 0
Study 31495231 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aerobic training
Number of subjects: 87
Study 31495231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aerobic training
Number of subjects: 87
Study 31495231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 87
Study 30832722 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/day vitamin D for 12 weeks
Number of subjects: 46
Study 30832722 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 46
Study 29882616 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-avoidance training (IG)
Number of subjects: 232
Study 29882616 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (CG)
Number of subjects: 232
Study 27417007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 300
Study 27417007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Number of subjects: 300
Study 27417007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 300
Study 27417007 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 300
Study 27417007 — intervention group
Group type: COMPARATOR
Intervention: Known predictors including CYP2C19 polymorphisms, age, body mass index, diabetes, and intrinsic platelet reactivity
Number of subjects: 300
Study 24779961 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD) aiming for 20 E% from carbohydrates
Number of subjects: 59
Study 24779961 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD) aiming for 55-60 E% from carbohydrates
Number of subjects: 59
Study 22653705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopaxar (50, 100, or 200 mg daily)
Number of subjects: 720
Study 22653705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study 20194812 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 416
Study 20194812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 18562985 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm with Acidform
Number of subjects: 192
Study 18562985 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm with placebo gel (HEC)
Number of subjects: 192
Study 18562985 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC applied intravaginally before sex
Number of subjects: 192
Study 18562985 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidform applied intravaginally before sex
Number of subjects: 192
Study 18562985 — intervention group
Group type: COMPARATOR
Intervention: Condoms (given to all participants)
Number of subjects: 192
Study 18562985 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm (general finding)
Number of subjects: 192
Study 18562985 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidform users (with or without diaphragm)
Number of subjects: 192
Study 15653582 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (balloon angioplasty alone or stenting)
Number of subjects: 283
Study 15653582 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 283
Study 15653582 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 283
Study 15653582 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment with severe stenosis
Number of subjects: 283
Study 15653582 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy patients with > or =70% stenosis
Number of subjects: 283
Study 12419136 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% metronidazol gel
Number of subjects: 27
Study 12419136 — intervention group
Group type: COMPARATOR
Intervention: Carbon fiber tip ultrasonic scaling
Number of subjects: 27
Study 10482995 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell non‐Hodgkin's lymphomas (NHL)
Number of subjects: 113
Study 10482995 — intervention group
Group type: EXPERIMENTAL
Intervention: Low grade NHL (small lymphocytic, follicular, mantle cell lymphoma)
Number of subjects: 113
Study 10482995 — intervention group
Group type: EXPERIMENTAL
Intervention: High grade NHL (diffuse large cell lymphoma)
Number of subjects: 113
Study 10482995 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant NHL B cell tumor growth
Number of subjects: 113
Study 8156342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 35
Study 8156342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 35
Study 8156342 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Number of subjects: 35
Study 8156342 — intervention group
Group type: COMPARATOR
Intervention: Pathological size correlation
Number of subjects: 35
Study 8156342 — intervention group
Group type: COMPARATOR
Intervention: Mammographic size correlation
Number of subjects: 35
Study 8156342 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographic size correlation
Number of subjects: 35
Study 3394962 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant of the psoas compartment block (Group 1)
Number of subjects: 50
Study 3394962 — intervention group
Group type: COMPARATOR
Intervention: Classic technique (Group 2)
Number of subjects: 50
Study 29533167 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language smoking cessation intervention (Libre del cigarillo, por mi familia y por mí: Guía para dejar de fumar)
Number of subjects: 0
Study 29533167 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group findings
Number of subjects: 0
Study 29533167 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner verification findings
Number of subjects: 0
Study 28008557 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex exercise
Number of subjects: 69
Study 28008557 — intervention group
Group type: COMPARATOR
Intervention: Conventional decongestive therapy
Number of subjects: 69
Study 25044235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of insulin 0.1U • kg‐1 • h‐1
Number of subjects: 73
Study 22770485 — intervention group
Group type: COMPARATOR
Intervention: Ambar (FGM) with Filtek Supreme Plus (FSP; 3M ESPE)
Number of subjects: 33
Study 22770485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (GC America)
Number of subjects: 33
Study 22770485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Nano (3M ESPE)
Number of subjects: 33
Study 20519751 — intervention group
Group type: EXPERIMENTAL
Intervention: Video self-instruction (self-learning group)
Number of subjects: 256
Study 20519751 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom instruction (classroom training group)
Number of subjects: 256
Study 18486414 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated format
Number of subjects: 6815
Study 18486414 — intervention group
Group type: EXPERIMENTAL
Intervention: Print format
Number of subjects: 6815
Study 18486414 — intervention group
Group type: COMPARATOR
Intervention: Interactive voice format
Number of subjects: 6815
Study 15797159 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective memory training
Number of subjects: 139
Study 15797159 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual memory training
Number of subjects: 139
Study 15797159 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 139
Study 12563194 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluder bifurcated endoprosthesis (test, n = 235)
Number of subjects: 334
Study 12563194 — intervention group
Group type: COMPARATOR
Intervention: Open surgical repair (control, n = 99)
Number of subjects: 334
Study 10462097 — intervention group
Group type: EXPERIMENTAL
Intervention: Community reinforcement training intervention
Number of subjects: 32
Study 10462097 — intervention group
Group type: COMPARATOR
Intervention: Popular 12-step self-help group
Number of subjects: 32
Study 8968177 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheal extubation (1-6 hours post-surgery)
Number of subjects: 100
Study 8968177 — intervention group
Group type: COMPARATOR
Intervention: Late tracheal extubation (12-22 hours post-surgery)
Number of subjects: 100
Study 1728908 — intervention group
Group type: COMPARATOR
Intervention: Weight reduction and placebo drug treatment
Number of subjects: 787
Study 1728908 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 787
Study 1728908 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of chlorthalidone
Number of subjects: 787
Study 1728908 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of atenolol
Number of subjects: 787